#LB0005 #EULAR2022 Phase 3 RCT of Bimekizumab, dual IL17A and 17F inhibitor in bDMARDs-naive PsA showed significant improvement in ACR50 and PASI90 scores vs Placebo. No major safety signals. Skin response is excellent! @RheumNow https://t.co/yhgB8LGXh6

#EULAR2022 LB0001 Bimekizumab (IL-17F and IL-17A) in bionaive PsA BE OPTIMAL phase 3 trial, 24 weeks ⭐️Met Primary endpt - ACR50 ⭐️Met other ACR and PASI endpts ⭐️Safety: higher fungal infections @RheumNow https://t.co/x8u6B93FNl

BE OPTIMAL Phase 3 RCT Bimekizumab dual IL17A & F inhibitor in bionaive PsA ⭐️ACR50 wk 16 43.9% vs 10% PBO ⭐️PASI 90 wk 16 61% vs. 3% PBO ⭐️separation from wk 4 Safety: fungal injections BKZ > ADA @RheumNow LB0001 #EULAR2022 https://t.co/7ZwV1XDSNb

CorEvitas PsA Registry (1000+ pts) Analysis of biologics prescription according to disease domains No real surprise to see that IL-17i were prescribed more frequently in pts w/ PsO BSA>10% at BL Overall first line TNFi 40% > IL-17i 14% POS0309 @RheumNow #EULAR2022 https://t.co/dkLxl8d6ug

Castrejon et al. BIOBADASER registry study. Cancer risk with various bDMARDs. Overall I don't think there is a difference here. Lowest in IL17i and highest in abatacept but older and comorbidity confounders @RheumNow #EULAR2022 #POS1439 https://t.co/gfv78ouOTJ

Izokibep - potent and small molecule IL-17A inhibitor Phase 2 study in PsA patients Fast onset, met ACR50 primary endpoint AE included site reaction and candida infection @RheumNow #EULAR2022 ABST#OP0258 https://t.co/vZ4xmnhyhl

52 wk trial using MSK Ultrasound study on PsA receiving secukinumab showed an early and continued improvement in GLOESS scores. Synovial hypertrophy most responsive. Hands and feet, wrist and knees most affected and responsive. @RheumNow #EULAR2022 ABST#OP0260 https://t.co/jeQezIWLxa

Merola et al. BE COMPLETE trial of bimekizumab (dual 17A/17Fi) in TNF-IR PsA. Week 16 ACR50: 43.4% BKZ vs 6.8% PBO. Rapid response with separation from week 4. @RheumNow #EULAR2022 OP0255 https://t.co/ZaxAeePP6L https://t.co/D5mDdkno3c

• EULAR Abstract Archive

Behrens et al. Izokibep (small molecular size IL17Ai, suggested to abrogate issues with tissue distribution of monoclonal abs) in PsA. ACR50 52% in 80mg, 48% in 40mg, 13% in PBO. @RheumNow #EULAR2022 https://t.co/FUS50ax79C https://t.co/e1n1RbNw1b

• EULAR Abstract Archive